According to the attached interview, Lilly,Norvartis,and Cephalon are also working on ALK inhibitors. I believe we are ahead of Lilly and Norvartis. http://pharmastrategyblog.com/2010/11/crizotinib-and-alk-rearrangements-in-lung-cancer-an-interview-with-dr-ross-camidge.html/